宫颈HC2-HPVDNA与宫颈TCT在宫颈癌筛查的临床应用分析

The clinical study of the HC2-HPVDNA detection and TCT examination on cervical cancer screening

目的：评价佛山市三水区人民医院HC2检测人乳头瘤病毒核酸（以下简称HC2）与宫颈薄层液基细胞学（TCT）检查预测宫颈癌前病变临床价值。方法：回顾性分析2014年9月~2015年2月我院妇科1683例患者检查HC2、TCT，对HC2阳性或TCT检查阳性均行阴道镜下宫颈活检病理结果综合分析。结果：205例HC2阳性，阳性率为12.18%，阳性预测值43.90%，138例TCT阳性，阳性率为8.19%，阳性预测值48.55%，联合检测阳性率为6.48%，阳性预测值64.22%。差异有统计学意义（P〈0.05）。结论：联合筛查阳性预测值明显提高，建议行联合筛查宫颈病变。

Objective：To evaluate the HC2 -HPVDNA detection（referred to as HC2 hereinafter）and TCT examination on cervical cancer screening in People’s Hospital of Sanshui District of Foshan City. Methods：We retrospectively reviewed the records of 1683 petients who join HC2 detection and TCT examination in our department from Septemper 2014 to February 2015. The persons who suffered one of them with abnormal results done vaginal microscopically cervical biopsy pathological examination. Results：The positive rate of single HC2 was 12.18% ,the positive predictive value was 43.90%. The positive rate of TCT single was 8.19%,the positive predictive value was 48.55%.The positive rate of combining both diagnosis was 6.48%,the positive predictive value was 64.22%,the difference was statistically（P〈0.05）.Conclusion ：The positive rate of combining both diagnosis was improved obviously,we suggest to combine both diagnosis on cervical cancer screening.